Continuum Therapeutics is enrolling the global phase two Propel IPF study of about 324 patients, targeting completion in 2028. About $245 million funds operations into 2029; Pipe 307 missed its MDD primary endpoint, and J&J is evaluating next steps.
CTNM · Contineum Therapeutics, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
PIPE-307/JNJ-89495120 did not achieve its primary efficacy endpoint in the September 2026 MOONLIGHT-1 trial, while PROPEL-IPF dosing began in the first quarter of 2026. The Company reported $244.5 million in cash, cash equivalents and marketable securities at September 30, 2026.
Contineum Therapeutics said the PROPEL-IPF trial of PIPE-791 had over 100 sites online in 16 countries, while $244.5 million in cash, cash equivalents and marketable securities was projected to fund operations through mid-2029.